CORDIS
EU research results

CORDIS

English EN
SPIDIA for Personalized Medicine - Standardisation of generic Pre-analytical procedures for In-vitro DIAgnostics for Personalized Medicine

SPIDIA for Personalized Medicine - Standardisation of generic Pre-analytical procedures for In-vitro DIAgnostics for Personalized Medicine

Objective

Molecular in vitro diagnostics and biomedical research have allowed great progress in personalised medicine but further progress is limited by insufficient guidelines for pre-analytical workflow steps (sample collection, preservation, storage, transport, processing etc.) as well as by insufficient quality assurance of diagnostic practice. This allows using compromised patients’ samples with post collection changes in cellular and extra-cellular biomolecules’ profiles thus often making diagnostic test results unreliable or even impossible. To tackle this, SPIDA4P aims to generate and implement a comprehensive portfolio of 22 pan-European pre-analytical CEN/Technical Specifications and ISO/International Standards, addressing the important pre-analytical workflows applied to personalized medicine. These will also applicable to biomarker discovery, development and validation as well as to biobanks. Corresponding External Quality Assurance (EQA) Schemes will be developed and implemented as well, aiming to survey the resulting quality of samples and diagnostic practice. SPIDIA4P will ensure stakeholder organisations involvements as well as training, education, and counselling as additional major foci of the project. The consortium will closely coordinate with large European public research consortia to obtain access to research and validation studies data serving as evidence for the new standards developments and achieved improvements of diagnosis, patient stratification and prognosis of disease outcome.
At this crucial moment in the development of personalised medicine, SPIDIA4P proposes a coordination and support action that reunites 19 highly experienced partners in international standardisation for in vitro diagnostics, coming from private industry including SMEs, public institutions and from one official European Standards Organisation. This strong consortium is balanced and empowered to maximise the impacts of in vitro diagnostics on personalised medicine.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

QIAGEN GMBH

Address

Qiagen Strasse 1
40724 Hilden

Germany

Activity type

Other

EU Contribution

€ 372 831,25

Participants (18)

Sort alphabetically

Sort by EU Contribution

Expand all

LGC LIMITED

United Kingdom

EU Contribution

€ 73 398,75

TECHNISCHE UNIVERSITAET MUENCHEN

Germany

EU Contribution

€ 100 875

DIN DEUTSCHES INSTITUT FUER NORMUNG E.V.

Germany

EU Contribution

€ 199 625

PREANALYTIX GMBH

Switzerland

INIVATA LIMITED

United Kingdom

CAMBRIDGE PROTEIN ARRAYS LTD

United Kingdom

EU Contribution

€ 97 000

TATAA BIOCENTER AB

Sweden

EU Contribution

€ 75 875

UNIVERSITA DEGLI STUDI DI FIRENZE

Italy

EU Contribution

€ 102 875

CONSORZIO INTERUNIVERSITARIO RISONANZE MAGNETICHE DI METALLO PROTEINE

Italy

EU Contribution

€ 61 375

UNIVERSITA DEGLI STUDI DI TRIESTE

Italy

EU Contribution

€ 84 750

UNIVERSITA DEGLI STUDI DI TORINO

Italy

EU Contribution

€ 78 375

BIOBANKS AND BIOMOLECULAR RESOURCESRESEARCH INFRASTRUCTURE CONSORTIUM(BBMRI-ERIC)

Austria

EU Contribution

€ 100 673,75

LUXEMBOURG INSTITUTE OF HEALTH

Luxembourg

EU Contribution

€ 152 500

MEDIZINISCHE UNIVERSITAT GRAZ

Austria

EU Contribution

€ 158 318,75

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 82 750

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

EU Contribution

€ 118 750

FUNDACIO CENTRE DE REGULACIO GENOMICA

Spain

EU Contribution

€ 88 750

FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI

Italy

EU Contribution

€ 51 250

Project information

Grant agreement ID: 733112

Status

Ongoing project

  • Start date

    1 January 2017

  • End date

    31 December 2020

Funded under:

H2020-EU.3.1.6.

  • Overall budget:

    € 2 079 053,75

  • EU contribution

    € 1 999 972,50

Coordinated by:

QIAGEN GMBH

Germany